Contact

Career
Country websites

Attention

The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

The product related information on the websites covers – unless explicitly stated otherwise – only CE marked products which are marketable in the European Union. Please be aware that not all products and services described on the following website are cleared or available for sale in all countries. Please check the relevant country web site for details.

By clicking the button “Accepted and Confirmed” you assure that you have taken note of this information.

Back to Homepage Accepted and Confirmed

Immunoadsorption

Treatment of autoimmune diseases

Treatment of autoimmune diseases

DISCLAIMER

Not all products and services are cleared or available for sale in all EU countries. Check your country web site for details. 

The product labels depicted may differ due to regulatory adaptations and changes in the legal form of the legal manufacturer.

Antibodies

Antibodies or autoantibodies often play a key role in solid organ transplantation and in autoimmune disorders. This is frequently associated with the activation or agonistic stimulation of cell-surface mechanisms (e.g. complement factors) or with antagonistic blockage of certain receptors. Immunoadsorption therapy removes antibodies or immune complexes from the blood plasma. Due to its selectivity, it can treat a wide range of autoantibody mediated clinical indications.1

During immunoadsorption, the targeted antibody classes are largely removed through strong binding affinity to different ligands of the adsorber matrix. This can alleviate the symptoms of disease, including in the acute state, and possibly prevent the disease’s progression.

GLOBAFFIN
Effective broad-spectrum immunoadsorption2,3

A number of serious diseases have an autoimmune pathophysiology and are sometimes difficult to treat, particularly when a quick and efficient elimination of autoantibodies is needed.

GLOBAFFIN

The GLOBAFFIN column is intended for the removal of immunoglobulins from the plasma of patients with specific autoantibodies associated with their disease.4

Treatment with GLOBAFFIN is characterized by:

  • Immunoadsorber with synthetic peptide ligand (peptide-GAM146)2
  • Twin adsorber system with multiple-use and multiple-pass characteristics
  • Semi-selective and efficient removal of IgG immunoglobulines5

 

Nephrology
Dermatology
Neurology

Medical Information

pdf

Immunoadsorption in COVID-19

PDF, 84 KB

Contact US

Close

Request a sales meet, demo or brochure by using this contact form

The information you provide will only be used to answer your query. For more information on how we process your Personal Data please read our privacy policy

This contact form is not intended to submit an adverse event related to medicinal products. To report an adverse event, please contact us at corporate-drug-safety(at)freseniusmedicalcare.com.

Related content

No Results Found
PREVIOUS
    NEXT

    1 Hamilton P et al. 2019, chapter 4 in Karkar A (ed.), Aspects in Continuous Renal Replacement Therapy. IntechOpen, London

    2 Rönspeck W et al. Ther Apher Dial 2003; 7(1):91-97

    3 Fuchs K et al. Ther Apher Dial 2022; 26:229-241

    4 Instructions for Use GLOBAFFIN, Ref. 35840034/5

    5 Biesenbach P et al. Atheroscler Suppl 2009; 10(5):114-121

    Contact
    Country websites

    All contact information

    Social Media

    © Fresenius Medical Care AG 2024

    Privacy policy

    Cookie settings

    Imprint